{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:20:09Z","timestamp":1761016809261},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.yebeh.2009.07.013","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T06:40:35Z","timestamp":1251355235000},"page":"240-245","source":"Crossref","is-referenced-by-count":18,"title":["Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: An indirect comparison of treatment-emergent adverse events using meta-analytic techniques"],"prefix":"10.1016","volume":"16","author":[{"given":"Florent F.","family":"Richy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soutrik","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Brabant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Helmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11 Suppl. 3","key":"10.1016\/j.yebeh.2009.07.013_bib1","first-page":"S11","article-title":"Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed?","volume":"55","author":"Bourgeois","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1525-5050(02)00037-9","article-title":"The relationship between poor medication compliance and seizures","volume":"3","author":"Cramer","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2009.07.013_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2009.07.013_bib4","first-page":"167","article-title":"Partial medication compliance. The enigma in poor medical outcomes","volume":"1","author":"Cramer","year":"1995","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.yebeh.2009.07.013_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eplepsyres.2005.09.033","article-title":"Bioequivalence in development of antiepileptic drugs","volume":"68","author":"Sommerville","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.07.013_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/13543784.15.6.637","article-title":"New antiepileptic drugs that are second generation to existing antiepileptic drugs","volume":"15","author":"Bialer","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.yebeh.2009.07.013_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00023210-200721090-00005","article-title":"Extended-release formulations for the treatment of epilepsy","volume":"21","author":"Bialer","year":"2007","journal-title":"CNS Drug"},{"key":"10.1016\/j.yebeh.2009.07.013_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0883073807302760","article-title":"Extended-release formulations in epilepsy","volume":"22","author":"Verroti","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2009.07.013_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yebeh.2004.01.009","article-title":"Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy","volume":"5","author":"Pellock","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2009.07.013_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-199400910-00002","article-title":"Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects","volume":"9","author":"Bareggi","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2009.07.013_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0920-1211(90)90088-D","article-title":"Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine","volume":"6","author":"Persson","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.07.013_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.yebeh.2006.02.006","article-title":"Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up","volume":"8","author":"McCabe","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2009.07.013_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2009.07.013_bib14","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 4","key":"10.1016\/j.yebeh.2009.07.013_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1528-1157.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial onset seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib18","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2009.07.013_bib20","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1167.2008.01981.x","article-title":"Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures","volume":"50","author":"Pi\u00f1a-Garza","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eplepsyres.2009.02.001","article-title":"Pharmacokinetics of levetiracetam XR 500mg tablets","volume":"84","author":"Rouits","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.07.013_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib27","series-title":"Introduction to meta-analysis","author":"Borenstein","year":"2008"},{"key":"10.1016\/j.yebeh.2009.07.013_bib28","series-title":"M\u00e9ta-analyse des essais th\u00e9rapeutiques","author":"Cucherat","year":"1997"},{"key":"10.1016\/j.yebeh.2009.07.013_bib29","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.yebeh.2009.07.013_bib30","unstructured":"Herbeuval AF, O\u2019Toul C. Meta-analysis on the levetiracetam (Keppra\u2122) adverse event and comparisons with lamotrigine fixed-effects and random-effects models. UCB Internal Report; 2002."},{"key":"10.1016\/j.yebeh.2009.07.013_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.yebeh.2009.07.013_bib32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00002018-200528100-00004","article-title":"Benefit\u2013risk assessment of levetiracetam in the treatment of partial seizures","volume":"28","author":"Abou-Khalil","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2009.07.013_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-1211(00)00158-3","article-title":"Efficacy and tolerability of 1000\u20134000mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy","volume":"42","author":"Grant","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.07.013_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2009.07.013_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.pnpbp.2007.10.015","article-title":"Effect of levetiracetam on depression and anxiety in adult epileptic patients","volume":"32","author":"Mazza","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2009.07.013_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1528-1157.2003.05402.x","article-title":"Topiramate and psychiatric adverse events in patients with epilepsy","volume":"44","author":"Mula","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.07.013_bib37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.07.013_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.07.013_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2009.07.013_bib40","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(06)69638-4","article-title":"Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses","volume":"368","author":"Chou","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2009.07.013_bib41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.yebeh.2009.07.013_bib42","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.yebeh.2009.07.013_bib43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2009.07.013_bib44","series-title":"Methods for meta-analysis in medical research","author":"Sutton","year":"2000"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505009003734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505009003734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T10:21:49Z","timestamp":1545042109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505009003734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S1525505009003734"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2009.07.013","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}